ACT-335827
Chemical compound
![]() | |
Clinical data | |
---|---|
Routes of administration | Oral |
Drug class | Orexin 1 receptor antagonist |
Identifiers | |
| |
PubChem CID |
|
ChemSpider |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C31H38N2O5 |
Molar mass | 518.654 g·mol−1 |
3D model (JSmol) |
|
| |
InChI
|
ACT-335827 is an orally available, selective orexin 1 receptor antagonist with anxiolytic effects in animals. Unlike other orexin receptor antagonists, ACT-335827 lacks sedative effects and was found to have no impact on sleep architecture in mice.[1][2]
References
- ^ Steiner MA, Gatfield J, Brisbare-Roch C, Dietrich H, Treiber A, Jenck F, Boss C (June 2013). "Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist". ChemMedChem. 8 (6): 898–903. doi:10.1002/cmdc.201300003. PMID 23589487. S2CID 21644009.
- ^ Merlo Pich E, Melotto S (2014). "Orexin 1 receptor antagonists in compulsive behavior and anxiety: possible therapeutic use". Frontiers in Neuroscience. 8: 26. doi:10.3389/fnins.2014.00026. PMC 3923148. PMID 24592206.
- v
- t
- e
- Antagonists: ACT-335827
- ACT-462206
- Almorexant
- AZD-4041
- C4X-3256 (INDV-2000)
- CR-5542
- CVN-766
- Daridorexant
- Fazamorexant (YZJ-1139)
- Filorexant
- GSK-649868 (SB-649868)
- Lemborexant
- Nivasorexant (ACT-539313)
- RTIOX-276
- SB-334867
- SB-408124
- Suvorexant
- TCS-1102
- Tebideutorexant (JNJ-61393215)
- Vornorexant (ORN-0829, TS-142)
- Agonists: AEX-19
- ALKS-2680
- Danavorexton (TAK-925)
- E-2086
- Firazorexton (TAK-994)
- Orexin (A, B)
- Oveporexton
- SB-668875
- Suntinorexton (TAK-861)
- Antagonists: ACT-335827
- ACT-462206
- Almorexant
- Daridorexant
- EMPA
- Fazamorexant (YZJ-1139)
- Filorexant
- GSK-649868 (SB-649868)
- JNJ-10397049
- Lemborexant
- MK-1064
- MK-3697
- MK-8133
- Seltorexant
- Suvorexant
- TCS-1102
- TCS-OX2-29
- Vornorexant (ORN-0829, TS-142)
![]() | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e